Low-Dose Melatonin Reduced Climacteric Symptoms by 15.8% — Withou

Low-Dose Melatonin Reduced Climacteric Symptoms by 15.8% — Without Touching FSH or Estradiol

A nightly dose of melatonin just 0.3 mg — a fraction of what’s sold in pharmacies — cut climacteric symptoms by 15.8% and improved sleep quality on days off by 35.3% in a randomized trial of 46 hospital nurses in São Paulo. Perhaps most striking for a menopause research audience: reproductive hormones didn’t move at all. Follicle-stimulating hormone (FSH), estradiol, luteinizing hormone (LH), and progesterone stayed flat. The benefits came through pathways that bypass the ovaries entirely.

What Happens to FSH and Estradiol During the Menopause Transition — and Why It Matters

To appreciate why this trial’s null hormone result is interesting, it helps to understand the hormonal cascade it studied. As ovarian function declines during perimenopause, follicles become resistant to FSH, the pituitary hormone that normally stimulates them. The pituitary responds by pumping out more and more FSH in an effort to keep estradiol production going. This is why consistently elevated FH above roughly 25–30 IU/L, alongside low estradiol, is a clinical marker of menopause.

The transition is rarely linear. Estradiol can swing wildly from cycle to cycle — sometimes spiking higher than in a woman’s twenties, sometimes crashing — which explains the erratic hot flashes, night sweats, and mood changes that define the climacteric. Large population studies, including recent cross-sectional work on sex- and age-specific hormonal patterns in healthy individuals, confirm that FSH rises steeply through the late reproductive years while estradiol and anti-Müllerian hormone fall in parallel. These swings have consequences beyond symptoms: FSH fluctuations during the transition have been linked to bone loss in women, and animal research even suggests some ovarian activity may persist after menopause.

The São Paulo Trial: 46 Nurses, Three Shifts, One Tiny Dose

Researchers at the University of São Paulo and the Federal University of São Paulo recruited nurses working fixed morning, afternoon, or night shifts and randomized them to 0.3 mg melatonin or placebo. The dose is physiologic — close to what the pineal gland naturally produces — roughly a tenth of typical over-the-counter supplements. Night-shift nurses took melatonin only on nights off, when sleeping at home, as did the day-shift groups. Blood samples collected at home measured LH, FSH, estradiol, and progesterone before and after the intervention.

Results split cleanly. Symptoms and sleep improved; hormones did not. The 15.8% symptom reduction held regardless of age or how long participants slept, and the effect did not depend on which shift a woman worked. Sleep quality gains were largest on rest days, and morning-shift workers benefited most. Night workers — whose circadian rhythms are chronically disrupted — showed no significant shift-specific benefit, a pattern consistent with what’s known about shift work’s toll on circadian health.

Why Melatonin Helps Without Changing Your Hormones

The mechanism here is circadian, not endocrine. Melatonin is the body’s darkness signal, secreted by the pineal gland at night and interpreted by receptors in the suprachiasmatic nucleus — the brain’s master clock. The hypothalamic-pituitary-gonadal axis and the circadian system are tightly intertwined: melatonin receptors sit on ovarian tissue and on GnRH-producing neurons, and circadian disruption can worsen climacteric symptoms independently of estrogen status.

By reinforcing circadian signaling — especially in women whose schedules fragment it — melatonin appears to stabilize sleep architecture and reduce symptom perception without reprogramming the reproductive axis. That matters clinically. Women who cannot or prefer not to take hormone therapy now have evidence for a low-cost, low-dose option that works through a different channel than estrogen replacement. It’s also worth noting what melatonin did not do: it didn’t lengthen sleep. Quality, not quantity, improved — suggesting effects on sleep depth and continuity rather than duration.

Practical Applications

• Dose matters. The trial used 0.3 mg. Many commercial supplements contain 5–10 mg, which can cause grogginess and hasn’t shown superior benefit in this context.
• Timing follows darkness. Melatonin was taken before sleep at home, on nights off — mimicking natural pineal secretion rather than forcing sleep at abnormal times.
• Shift workers should set expectations. Benefits were strongest for day-shift workers. Night-shift workers may need broader circadian strategies, not melatonin alone.
• It’s not a hormone replacement. FSH and estradiol remained unchanged, so melatonin won’t address bone density, vaginal health, or other estrogen-dependent concerns — for those, transdermal estrogen remains the best-evidenced option.
• Small trial, honest caveats. Forty-six participants over a short intervention is a modest sample, and the trial was registered retrospectively. Replication in larger, longer studies is needed before firm dosing recommendations.

Frequently Asked Questions

Can melatonin replace hormone therapy for menopause symptoms?

No. Melatonin improved symptoms and sleep in this trial but left FSH and estradiol unchanged, so it doesn’t provide the systemic benefits of estrogen on bone, heart, and vaginal tissue.

How much melatonin was used in the study?

Just 0.3 mg — a physiologic dose close to natural pineal output and far below the 5–10 mg found in many supplements.

Does melatonin affect FSH or estradiol levels?

In this trial, no. LH, FSH, estradiol, and progesterone all remained statistically unchanged after supplementation.

Does melatonin work for night-shift workers in menopause?

Less clearly. Benefits concentrated in day-shift workers; night workers’ chronically disrupted circadian rhythms appear to blunt melatonin’s effects.

Sources:
https://pubmed.ncbi.nlm.nih.gov/41841489/
https://pubmed.ncbi.nlm.nih.gov/41673051/
https://pubmed.ncbi.nlm.nih.gov/41568256/
https://pubmed.ncbi.nlm.nih.gov/41561822/
https://pubmed.ncbi.nlm.nih.gov/41504257/